Evidence map›Paper›PMID 32524303›Full record

ArticleJournal of gastrointestinal cancer2021

To Study the Anti-cancer Effects of Shigella Flexneri in AspC-1 Pancreatic Cancer Cell Line in Approach to Bax and bcl-2 Genes.

Amir Khodavirdipour, Fahimeh Jamshidi, Hamideh Rouhani Nejad, Masoud Zandi, Rana Zarean

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Amir KhodavirdipourDivision of Human Genetics, Department of Anatomy, St. John's Hospital, Bangalore, India.
Fahimeh JamshidiDepartment of Microbiology, Faculty of Basic Sciences, Islamic Azad University, Hamadan, Iran.
Hamideh Rouhani NejadThe Lister Laboratory of Microbiology, Tehran, Iran. rohaninejhad@gmail.com.ORCID http://orcid.org/0000-0002-8353-6542
Masoud ZandiDepartment of Microbiology, Faculty of Basic Sciences, Islamic Azad University, Hamadan, Iran.
Rana ZareanDepartment of Biotechnology, Faculty of Biology, Rab'e Rashid University, Tabriz, Iran.
Islamic Azad University of Hamedan · IRUniversity of Tabriz · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCancer is the uncontrolled division of cells and can be caused by genetic or environmental factors. Pancreatic cancer is one of the deadliest among all cancers. The role of bacteria as an anticancer agent dates back to almost 100 years ago. The microbiome has recently become a focus of research in carcinogenesis and even pancreatic cancer. Shigella flexneri is a gram-negative bacterium, which causes shigellosis with symptoms such as diarrhea, fever, and stomach cramps in human. Shigella flexneri may play a very important role in the internal pathways of apoptosis and may induce apoptosis in some of the cancerous cells. MATERIAL AND

methodsIn this experiment bacteria were cultured on Salmonella-Shigella agar, then inoculated into BHI Broth medium. After sonication, the protein concentration of the bacterium was measured by using the ZellBio Sensitive Protein Bradford Assay kit. MTT assay was performed to obtain IC

resultsThe results showed that Shigella flexneri has the potential anti-proliferative effect in pancreatic cancer. The inhibitory concentration, pro-apoptotic amount to upregulate Bax, and meanwhile also to downregulate the bcl-2 found to be 10 μl.

conclusionIn general, due to defects in the apoptotic pathway in cancer cells and the existence of drug-resistant cells, the detection of new apoptotic inducers such as Shigella flexneri cell extract can be used for further studies on cancer therapy.

Indexed as

Shigella flexneriApoptosisBacterial Proteinsbcl-2-Associated X ProteinBiological FactorsCell Line, TumorDown-RegulationDrug Screening Assays, AntitumorGene Expression Regulation, NeoplasticHumansInhibitory Concentration 50Pancreatic NeoplasmsProto-Oncogene Proteins c-bcl-2Up-RegulationBacterial ProteinsBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanBiological FactorsProto-Oncogene Proteins c-bcl-2ApoptosisCancer treatmentChemotherapeutic agentPancreatic cancerReal-time PCRShigella flexneri

Identifiers

PMID32524303
OpenAlexW3033831305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.